“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients. The trial is open at two sites in Ohio. To learn more about this clinical trial, click here: Pomalidomide and TEW-7197 Clinical Trial
about the author
MyelomaCrowd Editorial Contributor. Daughter to a parent with cancer.